{"id":25625,"date":"2022-09-19T01:46:00","date_gmt":"2022-09-18T17:46:00","guid":{"rendered":"https:\/\/flcube.com\/?p=25625"},"modified":"2025-02-06T01:52:41","modified_gmt":"2025-02-05T17:52:41","slug":"apollomics-set-to-merge-with-maxpro-capital-for-nasdaq-listing","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=25625","title":{"rendered":"Apollomics Set to Merge with Maxpro Capital for Nasdaq Listing"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Sino-US biotech Apollomics Inc. has revealed plans to merge with the special purpose acquisition company (SPAC) Maxpro Capital Acquisition Corp., paving the way for a public listing on the Nasdaq stock exchange. The transaction values Apollomics at a pre-money equity of $899 million, with the company expecting to retain up to $105 million in cash to further expand its pipeline, including through partnerships. The deal is anticipated to close in Q1 2023, at which time Apollomics will list under the ticker APLM. The transaction is subject to approval from Maxpro shareholders and other customary closing conditions.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Company Overview and Pipeline<\/strong><br>Apollomics is officially based in Foster City, California, but maintains a strong presence in China, with operations in Shanghai and Hangzhou. The company is backed by a range of Chinese investors, including Ping An Capital, China Renaissance, and CMB International. Apollomics has nine pipeline assets under development, including both small-molecule drugs and biologics. The pipeline is led by vebreltinib, a proto-oncogene hepatocyte growth factor receptor (c-Met) inhibitor in pivotal Phase II studies for non-small cell lung cancer (NSCLC), which is expected to support a subsequent US NDA filing. Additionally, uproleselan, an E-selectin antagonist, is in Phase III studies in China for relapsed or refractory acute myeloid leukemia (AML).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Maxpro Capital and SPAC Structure<\/strong><br>Maxpro Capital is a &#8216;blank cheque&#8217; company formed for the purpose of effecting a merger, capital share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses in the healthcare and technology industries. The merger with Apollomics represents a strategic step for both companies, positioning Apollomics for expanded access to capital markets and further growth.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Sino-US biotech Apollomics Inc. has revealed plans to merge with the special purpose acquisition company&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[1927,30,20,72],"class_list":["post-25625","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-apollomics","tag-biotech","tag-finance","tag-ipo"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Apollomics Set to Merge with Maxpro Capital for Nasdaq Listing - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Sino-US biotech Apollomics Inc. has revealed plans to merge with the special purpose acquisition company (SPAC) Maxpro Capital Acquisition Corp., paving the way for a public listing on the Nasdaq stock exchange. The transaction values Apollomics at a pre-money equity of $899 million, with the company expecting to retain up to $105 million in cash to further expand its pipeline, including through partnerships. The deal is anticipated to close in Q1 2023, at which time Apollomics will list under the ticker APLM. The transaction is subject to approval from Maxpro shareholders and other customary closing conditions.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=25625\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Apollomics Set to Merge with Maxpro Capital for Nasdaq Listing\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=25625\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-18T17:46:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-02-05T17:52:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25625#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25625\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Apollomics Set to Merge with Maxpro Capital for Nasdaq Listing\",\"datePublished\":\"2022-09-18T17:46:00+00:00\",\"dateModified\":\"2025-02-05T17:52:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25625\"},\"wordCount\":284,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Apollomics\",\"Biotech\",\"Finance\",\"IPO\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=25625#respond\"]}],\"copyrightYear\":\"2022\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25625\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=25625\",\"name\":\"Apollomics Set to Merge with Maxpro Capital for Nasdaq Listing - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2022-09-18T17:46:00+00:00\",\"dateModified\":\"2025-02-05T17:52:41+00:00\",\"description\":\"Sino-US biotech Apollomics Inc. has revealed plans to merge with the special purpose acquisition company (SPAC) Maxpro Capital Acquisition Corp., paving the way for a public listing on the Nasdaq stock exchange. The transaction values Apollomics at a pre-money equity of $899 million, with the company expecting to retain up to $105 million in cash to further expand its pipeline, including through partnerships. The deal is anticipated to close in Q1 2023, at which time Apollomics will list under the ticker APLM. The transaction is subject to approval from Maxpro shareholders and other customary closing conditions.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25625#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=25625\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25625#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Apollomics Set to Merge with Maxpro Capital for Nasdaq Listing\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Apollomics Set to Merge with Maxpro Capital for Nasdaq Listing - Insight, China&#039;s Pharmaceutical Industry","description":"Sino-US biotech Apollomics Inc. has revealed plans to merge with the special purpose acquisition company (SPAC) Maxpro Capital Acquisition Corp., paving the way for a public listing on the Nasdaq stock exchange. The transaction values Apollomics at a pre-money equity of $899 million, with the company expecting to retain up to $105 million in cash to further expand its pipeline, including through partnerships. The deal is anticipated to close in Q1 2023, at which time Apollomics will list under the ticker APLM. The transaction is subject to approval from Maxpro shareholders and other customary closing conditions.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=25625","og_locale":"en_US","og_type":"article","og_title":"Apollomics Set to Merge with Maxpro Capital for Nasdaq Listing","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=25625","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2022-09-18T17:46:00+00:00","article_modified_time":"2025-02-05T17:52:41+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=25625#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=25625"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Apollomics Set to Merge with Maxpro Capital for Nasdaq Listing","datePublished":"2022-09-18T17:46:00+00:00","dateModified":"2025-02-05T17:52:41+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=25625"},"wordCount":284,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Apollomics","Biotech","Finance","IPO"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=25625#respond"]}],"copyrightYear":"2022","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=25625","url":"https:\/\/flcube.com\/?p=25625","name":"Apollomics Set to Merge with Maxpro Capital for Nasdaq Listing - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2022-09-18T17:46:00+00:00","dateModified":"2025-02-05T17:52:41+00:00","description":"Sino-US biotech Apollomics Inc. has revealed plans to merge with the special purpose acquisition company (SPAC) Maxpro Capital Acquisition Corp., paving the way for a public listing on the Nasdaq stock exchange. The transaction values Apollomics at a pre-money equity of $899 million, with the company expecting to retain up to $105 million in cash to further expand its pipeline, including through partnerships. The deal is anticipated to close in Q1 2023, at which time Apollomics will list under the ticker APLM. The transaction is subject to approval from Maxpro shareholders and other customary closing conditions.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=25625#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=25625"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=25625#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Apollomics Set to Merge with Maxpro Capital for Nasdaq Listing"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/25625","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=25625"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/25625\/revisions"}],"predecessor-version":[{"id":25626,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/25625\/revisions\/25626"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=25625"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=25625"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=25625"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}